Hikma Pharmaceuticals PLC (LON:HIK)
United Kingdom · Delayed Price · Currency is GBP · Price in GBX | Market Cap | 3.38B -3.6% |
| Revenue (ttm) | 2.58B +6.3% |
| Net Income | 291.68M +4.3% |
| EPS | 1.32 +5.3% |
| Shares Out | 207.23M |
| PE Ratio | 12.30 |
| Forward PE | 9.07 |
| Dividend | 0.62 (3.81%) |
| Ex-Dividend Date | Aug 13, 2026 |
| Volume | 563,492 |
| Open | 1,612.00 |
| Previous Close | 1,625.00 |
| Day's Range | 1,609.00 - 1,635.00 |
| 52-Week Range | 1,187.00 - 1,762.00 |
| Beta | 0.62 |
| Analysts | Strong Buy |
| Price Target | 1,979.71 (+21.46%) |
| Est. Earnings | Nov 13, 2026 |
About Hikma Pharmaceuticals
Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, specialty, and branded pharmaceutical products. The company operates through three segments: Injectables, Hikma Rx, and Branded. The Injectables segment provides generic and specialty injectable products primarily for use in hospitals. The Branded segment offers branded generics and in-licensed products to retail and hospital markets. The Hikma Rx segment offers oral, respiratory, and other generic and specialty products for the retail market. It provides i... [Read more]
Full Company ProfileFinancial Performance
In 2025, Hikma Pharmaceuticals's revenue was $3.35 billion, an increase of 7.10% compared to the previous year's $3.13 billion. Earnings were $402.00 million, an increase of 11.98%.
Financial numbers in USD Financial StatementsAnalyst Summary
According to 12 analysts, the average rating for HIK stock is "Strong Buy." The 12-month stock price target is 1,980p, which is an increase of 21.46% from the latest price.
News
Hikma Pharmaceuticals Raises Profit Floor as Branded Growth Offsets Injectables Slowdown
Hikma Pharmaceuticals LON: HIK maintained its 2026 revenue growth outlook and narrowed its operating profit guidance as stronger performance in its Branded business helped offset a slower-than-expecte...
Hikma Pharmaceuticals Transcript: Trading update
FY26 revenue growth guidance remains 2%-4%, with the operating profit range narrowed to $740m-$760m. Branded is set for ~10% growth, while Injectables expects modest growth in 2027 as TYZAVAN gains traction.
Hikma Pharmaceuticals Earnings release: Trading update
Hikma Pharmaceuticals released its earnings on November 5, 2026, summarizing the period's financial results.
Hikma Raises Branded Growth Outlook, Narrows 2026 Profit Guidance
(RTTNews) - Hikma Pharmaceuticals PLC (HIK.L) said trading remains in line with expectations and narrowed its full-year 2026 core operating profit outlook, supported by strong performance in its Brand...
UK's Hikma tightens annual profit outlook as branded medicines drive growth
Britain's Hikma Pharmaceuticals on Thursday narrowed its annual profit forecast range closer to the higher end as strong demand in its branded business across in the Middle East and North Africa off...
Hikma Pharmaceuticals PLC - Depositary Receipt Price Target Decreased by 17.53% to $51.72
The average one-year price target for Hikma Pharmaceuticals PLC - Depositary Receipt (OTCPK:HKMPY) (DB:H5PA) has been revised to $51.72 / share. This is a decrease of 17.53% from the prior estimate of...
Hikma Pharmaceuticals Spotlights R&D Shift, Nasal Epinephrine Filing Progress
Hikma Pharmaceuticals LON: HIK outlined a more centralized research and development strategy at the first event in its R&D Spotlight series, highlighting investments in respiratory, nasal, semi-solid ...
Hikma Pharmaceuticals Transcript: Investor update
A centralized, specialized R&D model is directing higher investment toward a mix of complex global programs and nearer-term opportunities, with returns reassessed through stage gates. Key pipeline updates include accepted U.S. review of intranasal epinephrine and continued Ellipta development.
Hikma Pharmaceuticals Slides: Investor update
Hikma Pharmaceuticals has posted slides in relation to its latest quarterly earnings report, which was published on October 20, 2026.
Hikma Pharmaceuticals price target lowered to 1,810 GBp from 1,870 GBp at Citi
Citi lowered the firm’s price target on Hikma Pharmaceuticals (HKMPF) to 1,810 GBp from 1,870 GBp and keeps a Buy rating on the shares.
Hikma advances its epinephrine nasal spray with multi-market regulatory filings
LONDON, Sept. 10, 2026 /PRNewswire/ -- Hikma Pharmaceuticals PLC (Hikma, Group) announces that regulatory submissions for its epinephrine nasal spray, being developed for the emergency treatment of al...
Hikma Pharmaceuticals upgraded to Equal Weight from Underweight at Barclays
Barclays analyst James Gordon upgraded Hikma Pharmaceuticals (HKMPF) to Equal Weight from Underweight with a price target of 1,700 GBp, up from 1,350 GBp. The company’s execution shortfalls and earnin...
Hikma Pharmaceuticals price target raised to 1,870 GBp from 1,700 GBp at Citi
Citi raised the firm’s price target on Hikma Pharmaceuticals (HKMPF) to 1,870 GBp from 1,700 GBp and keeps a Buy rating on the shares.
Hikma price target raised to 2,100 GBp from 1,800 GBp at Berenberg
Berenberg raised the firm’s price target on Hikma Pharmaceuticals (HKMPF) to 2,100 GBp from 1,800 GBp and keeps a Buy rating on the shares.
Hikma Pharmaceuticals H1 Earnings Call Highlights
Hikma Pharmaceuticals LON: HIK said it reiterated its full-year guidance after reporting higher sales, earnings and per-share profit in its 2026 interim results, while outlining further investment in ...
Hikma Pharmaceuticals Earnings Call Transcript: H1 2026
Sales, EBIT, and EBITDA rose year-over-year, with strong MENA and Rx performance offsetting headwinds elsewhere. Full-year guidance is reiterated, with higher H2 investment expected and CMO revenues set to increase. Risks include MENA instability and post-stockpiling normalization.
Hikma Pharmaceuticals Quarterly report: H1 2026
Hikma Pharmaceuticals has published its H1 2026 quarterly earnings report on August 6, 2026.
Hikma Pharmaceuticals Slides: H1 2026
Hikma Pharmaceuticals has posted slides in relation to its H1 2026 quarterly earnings report, which was published on August 6, 2026.
UK's Hikma Pharma holds annual outlook, preps for US generic drug tariffs
Britain's Hikma Pharmaceuticals reported a 9% rise in half-year core-operating profit and maintained its annual outlook on Thursday, supported by the generic drugmaker's turnaround efforts to expand...
Shares in Generic-Drug Makers Fall After Trump's Tariff Plan
Shares in several European and Asian makers of generic medicines fell after President Trump said the U.S. would place tariffs on such drugs starting in August 2028.
Hikma Pharmaceuticals initiated with a Buy at Citi
Citi initiated coverage of Hikma Pharmaceuticals (HKMPF) with a Buy rating and 1,700 GBp price target The firm sees a “compelling” entry point at current share levels. Published first on…
Hikma comments on Supreme Court of the United States' unanimous decision in favour of Hikma
LONDON, June 4, 2026 /PRNewswire/ -- Hikma Pharmaceuticals PLC, along with its wholly owned subsidiary Hikma Pharmaceuticals USA Inc., (Hikma) offered the following comments on today's unanimous decis...
US Supreme Court backs generic drugmaker in 'skinny label' patent case
The U.S. Supreme Court ruled on Thursday drugmaker Hikma's generic version of Amarin Pharma's cardiovascular medication Vascepa did not infringe Amarin's patents, in a decision that may make generic...
Hikma Pharmaceuticals Announces Major Expansion in Ohio, Creating 350 New Jobs and Investing $267 Million
Cleveland and Columbus, Ohio, June 01, 2026 (GLOBE NEWSWIRE) -- COLUMBUS and CLEVELAND, Ohio – Ohio Governor Mike DeWine, along with Hikma Pharmaceuticals, JobsOhio, the City of Bedford, and other sta...
Hikma Pharmaceuticals Transcript: Trading update
Performance is in line with expectations, with robust demand and reiterated 2026 guidance. Strategic focus includes exiting the 503B business, investing in R&D, and expanding capacity. Middle East demand is strong, inflation is managed, and biosimilars lead in MENA.